Genenta Science S.p.A., a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for solid tumors, including the lead product candidate, Temferon™, rang the closing bell at the NASDAQ Stock Exchange. Growth Capital has advised Genenta’s management team.
Genenta at NASDAQ! Growth Capital has advised Genenta’s management team
Dicembre 21, 2021